{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06460961",
            "orgStudyIdInfo": {
                "id": "6837-001"
            },
            "secondaryIdInfos": [
                {
                    "id": "MK-6837-001",
                    "type": "OTHER",
                    "domain": "Merck"
                }
            ],
            "organization": {
                "fullName": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)",
            "officialTitle": "A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-mk-as-a-monotherapy-and-combination-therapy-in-participants-with-advanced-metastatic-solid-tumors-mk"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-07-13",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-07-13",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-11",
            "studyFirstSubmitQcDate": "2024-06-11",
            "studyFirstPostDateStruct": {
                "date": "2024-06-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not responded to conventional therapy. There will not be any hypothesis testing in the study."
        },
        "conditionsModule": {
            "conditions": [
                "Neoplasm Metastasis"
            ],
            "keywords": [
                "Programmed Cell Death-1 (PD1, PD-1)",
                "Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)",
                "Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1: MK-6837 Monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive escalating doses of MK-6837 via intravenous (IV) infusion once every 3 weeks (Q3W) (Day 1 of every 21-day cycle) until progressive disease or discontinuation.",
                    "interventionNames": [
                        "Biological: MK-6837"
                    ]
                },
                {
                    "label": "Arm 2: MK-6837 + Pembrolizumab Combination Therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive escalating doses of MK-6837 via IV infusion Q3W (Day 1 of every 21-day cycle) until progressive disease or discontinuation PLUS 200mg of pembrolizumab via IV infusion Q3W (Day 1 of every 21-day cycle) for up to 35 administrations (up to \\~2 years).",
                    "interventionNames": [
                        "Biological: MK-6837",
                        "Biological: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "MK-6837",
                    "description": "IV Infusion",
                    "armGroupLabels": [
                        "Arm 1: MK-6837 Monotherapy",
                        "Arm 2: MK-6837 + Pembrolizumab Combination Therapy"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Pembrolizumab",
                    "description": "IV Infusion",
                    "armGroupLabels": [
                        "Arm 2: MK-6837 + Pembrolizumab Combination Therapy"
                    ],
                    "otherNames": [
                        "MK-3475",
                        "KEYTRUDA\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants who experience one or more dose-limiting toxicities (DLTs)",
                    "description": "The following events will be considered a DLT unless clearly due to underlying disease or extraneous causes: Grade 4 neutropenia lasting \\>7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding, regardless of duration; All Grade 3 or higher nonhematologic toxicities (with exceptions); Any abnormality that results in a drug induced liver injury; Febrile neutropenia Grade 3 or 4; Prolonged delay (\\>2 weeks) in initiating treatment after the first 21 days due to intervention-related toxicity; Any intervention-related toxicity that causes the participant to discontinue intervention during the first 21 days; Grade 5 toxicity. The number of participants who experience a DLT will be presented.",
                    "timeFrame": "Cycle 1 (Up to approximately 21 days); each cycle is 21 days."
                },
                {
                    "measure": "Number of participants who experience one or more adverse events (AEs)",
                    "description": "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.",
                    "timeFrame": "Up to approximately 59 months"
                },
                {
                    "measure": "Number of participants who discontinue study intervention due to an AE",
                    "description": "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.",
                    "timeFrame": "Up to approximately 59 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum concentration (Cmax) of MK-6837 in plasma",
                    "description": "The Cmax of MK-6837 in plasma will be determined.",
                    "timeFrame": "Day 1 of cycles 1 and 4: Predose, ~30 minutes, 1, 2, and 4 hours postdose and once daily on Days 2, 3, 5, 8, 11, and 15 postdose; Cycles 2, 3, 5, 6, and every 6 cycles thereafter (up to ~59 months): predose and ~30 minutes postdose; each cycle is 21 days"
                },
                {
                    "measure": "Minimum concentration (Ctrough) of MK-6837 in plasma",
                    "description": "The Ctrough of MK-6837 in plasma will be determined.",
                    "timeFrame": "Day 1 of cycles 1 and 4: Predose, ~30 minutes, 1, 2, and 4 hours postdose and once daily on Days 2, 3, 5, 8, 11, and 15 postdose; Cycles 2, 3, 5, 6, and every 6 cycles thereafter (up to ~59 months): predose and ~30 minutes postdose; each cycle is 21 days"
                },
                {
                    "measure": "Area Under the Concentration-Time Curve (AUC) of MK-6837 in plasma",
                    "description": "The AUC of MK-6837 in plasma will be determined.",
                    "timeFrame": "Day 1 of cycles 1 and 4: Predose, ~30 minutes, 1, 2, and 4 hours postdose and once daily on Days 2, 3, 5, 8, 11, and 15 postdose; Cycles 2, 3, 5, 6, and every 6 cycles thereafter (up to ~59 months): predose and ~30 minutes postdose; each cycle is 21 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Histologically or cytologically confirmed solid tumor by pathology report that is advanced or metastatic\n* Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on Antiretroviral Therapy (ART)\n* Participants who are Hepatitis B Surface Antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load before allocation\n* Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from any Adverse Events (AEs) that were due to cancer therapeutics administered more than 4 weeks earlier\n* History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years\n* Has clinically significant cardiovascular disease\n* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease\n* Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention\n* Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related AE (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis\n* Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention\n* Known additional malignancy that is progressing or has required active treatment within the past 2 years\n* Known active Central Nervous System (CNS) metastases and/or carcinomatous meningitis\n* Active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy\n* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease\n* Active infection requiring systemic therapy\n* History of allogeneic tissue/solid organ transplant\n* Participants who have not adequately recovered from major surgery or have ongoing surgical complications",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Toll Free Number",
                    "role": "CONTACT",
                    "phone": "1-888-577-8839",
                    "email": "Trialsites@merck.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Merck Sharp & Dohme LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Atlantic Health System Morristown Medical Center ( Site 4001)",
                    "status": "RECRUITING",
                    "city": "Morristown",
                    "state": "New Jersey",
                    "zip": "07960",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "862-345-8666"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.79677,
                        "lon": -74.48154
                    }
                },
                {
                    "facility": "Sheba Medical Center-ONCOLOGY ( Site 3001)",
                    "status": "RECRUITING",
                    "city": "Ramat Gan",
                    "zip": "5265601",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "97235307039"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08227,
                        "lon": 34.81065
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Merck Clinical Trials Information",
                    "url": "https://www.merckclinicaltrials.com/"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf",
            "url": "http://engagezone.msd.com/ds_documentation.php"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009362",
                    "term": "Neoplasm Metastasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6845",
                    "name": "Death",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "asFound": "Neoplasm Metastasis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}